Epizyme (EPZM) – Business Wire
-
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
-
Ipsen to acquire Epizyme, expanding its portfolio in oncology
-
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
-
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
-
Epizyme To Participate in H.C. Wainwright Global Investment Conference
-
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
-
Epizyme Announces Date of First Quarter 2022 Financial Results
-
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
-
Epizyme to Participate in Upcoming Healthcare Conferences in March
-
Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
-
Epizyme Announces Pricing of Public Offering of Common Stock
-
Epizyme Announces Proposed Public Offering of Common Stock
-
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
-
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
-
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
-
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
-
Epizyme Announces Updates to Its Board of Directors
-
Epizyme to Participate in Jefferies London Healthcare Conference
-
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
-
Epizyme Announces Date of Third Quarter 2021 Financial Results
-
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
-
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
-
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Epizyme Announces CEO Succession
-
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
-
Epizyme Announces Date of Second Quarter 2021 Financial Results
-
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
-
Epizyme to Participate in Jefferies Virtual Healthcare Conference
-
Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June
-
Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
-
Epizyme Announces Date of First Quarter 2021 Financial Results
-
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call
-
Epizyme to Host Strategic Vision Call on March 2, 2021
-
CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
-
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
-
Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
-
Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development
-
Epizyme to Participate in Jefferies Virtual London Healthcare Conference
-
Epizyme Reports Business Progress and Third Quarter 2020 Financial Results
-
Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives
-
Epizyme Announces Date of Third Quarter 2020 Financial Results
-
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
-
Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference
Back to EPZM Stock Lookup
